Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
25 March, 2019 13:47 IST
Zydus Cadila gets tentative nod for Sitagliptin tablets
Source: IRIS | 11 Sep, 2018, 01.42PM
Comments  |  Post Comment

Zydus Cadila has received the tentative approval from the USFDA for Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg (US RLD-Januvia Tablets). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Sitagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high.

The group now has 217 approvals and has so far filed over 330 ANDAs since the commencement ofthe filing process in FY 2003-04.

Shares of the company declined Rs 2.6, or 0.62%, to trade at Rs 418.20. The total volume of shares traded was 128,834 at the BSE (1.33 p.m., Tuesday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer